Scientists are a step closer to being able to cure the deadly Ebola haemorrhagic fever after two experimental drugs showed survival rates of as much as 90% in a clinical trial in Congo.
Two experimental drugs - an antibody cocktail called REGN-EB3 developed by Regeneron and a monoclonal antibody
```
Members Only
Login or create an account to continue
This article is available to registered BusinessDay readers. Please login if you already have an account, or create a new account to continue reading.
New to BusinessDay? Register now and start reading.
```
